Form 4: Vericel Corp Executive Sean C. Flynn Reports Stock Transactions
SEC Form 4
Chief Legal Officer Sean C. Flynn reports acquisition and disposal of Vericel Corp stock and restricted stock units due to vesting and tax withholding.
Summary
- On February 18 and 19, 2025, Sean C. Flynn, Chief Legal Officer of Vericel Corp, reported transactions involving the company's common stock and restricted stock units (RSUs).
- Flynn acquired shares of common stock through the vesting of RSUs granted on February 17, 2023, February 18, 2022, and February 19, 2021.
- The vesting of 3,000 RSUs on February 18, 2025, resulted in the acquisition of 3,000 shares at $0.
- An additional 2,325 shares were acquired on February 18, 2025, due to the vesting of RSUs, also at $0.
- On February 19, 2025, 1,750 shares were acquired through the vesting of RSUs at $0.
- Flynn also disposed of shares to cover tax withholding requirements related to the vesting of RSUs.
- On February 18, 2025, 1,431 shares were disposed of at a price of $57.28.
- Another 1,032 shares were disposed of on February 18, 2025, at $57.28.
- On February 19, 2025, 777 shares were disposed of at $57.78.
- Following these transactions, Flynn directly owns 4,591 shares of Vericel Corp common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.
Positives
- The vesting of RSUs indicates that Flynn is meeting the conditions of his equity compensation plan.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Comparison to Industry Standards
- Executive compensation packages often include RSUs as a way to align management's interests with those of shareholders.
- The vesting schedules and tax withholding practices are standard across many publicly traded companies.
- Similar filings can be observed for executives at companies like CRISPR Therapeutics and Editas Medicine, which also operate in the biotechnology space.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and do not represent a significant change in the company's operations or financial condition.
Key Dates
| Date | Description |
|---|---|
| 02/17/2023 | Date of RSU grant, with remaining RSUs vesting on February 17, 2026, and February 17, 2027. |
| 02/18/2022 | Date of RSU grant, with remaining RSUs vesting on February 18, 2026. |
| 02/19/2021 | Date of RSU grant. |
| 02/18/2025 | Date of transactions involving acquisition and disposal of common stock and RSUs. |
| 02/19/2025 | Date of transactions involving acquisition and disposal of common stock and RSUs. |
| 02/20/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.